Cereno Scientific reports positive results from the data quality control review initiative in the Phase II study of CS1 in rare disease pulmonary arterial hypertension (PAH)
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the initiative to control the data quality produced from the cutting-edge technology CardioMEMS HF System (Abbott Inc.) used in the Phase II study of CS1 in pulmonary arterial hypertension (PAH) has successfully been concluded with positive results. The Data Quality Control Review (DQCR) found the data quality of the CardioMEMS measurements satisfactory with adherence to study protocol and with timely data transfers from the patient's home